Medical Programs

Mesothelioma
Last Updated: February 9, 2007
Get CME/CE for article

Background: Mesothelial cells normally line the body cavities, including the pleura, peritoneum, pericardium, and testis. Malignancies involving mesothelial cells in these body cavities are known as malignant mesothelioma, which may be localized or diffuse. Diagnosis is difficult because the results from fluid analysis of the effusion from the tumor are not usually diagnostic. Most, but not all, pleural malignant mesothelioma is associated with asbestos exposure. Of patients with pleural malignant mesothelioma, 77% have been exposed to asbestos in the past. Mesothelioma is more common in males than in females and it occurs in the fifth and seventh decade of life. Most of malignant mesothelioma occur in the pleura (90% of the time).

Get CME/CE for article

Complimentary Accredited Web Archive

Target Audience:
This activity has been developed for physicians.

Learning Objectives:
Upon completion of this educational activity, participants should be able to:

-discuss the concept of CT overlay on fluoroscopic images
-describe the limitations of CT overlayOn-Demand

Accreditation:

MD/DO:
This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

On-Demand

All MedPro programs are 100% client-branded to provide greater emphasis on your company and increase the potential impact on your target audience. In addition, MedPro programs are easy-to-use for your presenter and your audience; our programs do not require any special software downloads that may limit participation. We have the right solution for your next program and we have the experience to show you the best way to make it happen.

Read the rest of this entry »

Alimta®/Platinum-compound Combination Confirmed Active in Mesothelioma
Cancer Consultants (press release), TN - Jun 26, 2007
Malignant pleural mesothelioma is a rare cancer that develops in the tissue that covers the lungs and lines the interior of the chest. …

Latest cancer deaths renew fears about mesothelioma
Tower Timberjay News, MN - Jun 29, 2007
By Marshall Helmberger That’s the question that remains at the heart of the debate over the apparent cluster of mesothelioma cases among former mine workers …

Read more…

Asbestos victims set for compensation boost
Building.co.uk (subscription), UK - 8 hours ago
Under the terms of the Bill, sufferers of mesothelioma, a form of lung cancer brought on by asbestos exposure, will be able to more quickly and easily claim …

Read more…

Net Cash Proceeds to be Used for CardioTech’s Growth Initiatives

July 05, 2007: 10:30 AM EST

WILMINGTON, Mass., July 5 /PRNewswire-FirstCall/ — CardioTech International, Inc. , a developer and manufacturer of advanced materials and medical devices for the treatment of cardiovascular and other diseases, announced today that it has signed an agreement to sell its Gish Biomedical, Inc. subsidiary in a stock transaction to Medos Medizintechnik AG (”Medos”) for a purchase price of approximately $7.5 million. Medos Medizintechnik AG, is a developer and manufacturer of medical devices for cardiac surgery, extracorporeal membrane oxygenation (ECMO) and Ventricle Assist Devices (VAD). Of the purchase price, $1.0 million will be held in a one-year cash escrow to fund CardioTech’s post-closing indemnification obligations to Medos, if any. After estimated transaction costs of $500,000 and the escrow funding, CardioTech expects to realize approximately $6.0 million in cash from the sale of Gish. The terms of the agreement provide that CardioTech retains all cash on Gish’s balance sheet. The sale of Gish is expected to close on or about July 9, 2007.

Read more… 

Abbott Northwestern Hospital could lose Medicare funding for heart transplants. The reason: Medicare says it doesn’t do enough of them.

By Maura Lerner, Star Tribune
Last update: July 04, 2007 – 3:26 PM

Abbott could lose Medicare funding for heart transplants

About:
Abbott Northwestern Hospital is the largest not-for-profit hospital in the Twin Cities area. Each year, the hospital provides comprehensive health care for more than 200,000 patients and their families from the Twin Cities area and throughout the Upper Midwest. Read more…

3 heart transplant programs get warning
Los Angeles Times, CA - Jul 3, 2007
… programs have agreed to forgo federal money, another five are operating under corrective plans approved by Medicare, and one, BryanLGH Medical Center …

3 heart transplant programs …full article

Dietary counseling can be effective
Earthtimes.org - 6 hours ago
Programs with more frequent meetings and greater calorie restrictions tended to produce greater weight losses over time, according to one of the study’s …

Dietary counseling…Full Article